Rate Video

EBMT 2020 | Tocilizumab: CAR T-cell therapy in DLBCL

Matthew Frigault • 1 Sep 2020

EBMT 2020

Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Tisagenlecleucel Tocilizumab

ELIANA Treatment Trial Updates

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR T-cell therapy for treatment of cytokine release syndrome (CRS) in refractory diffuse large B-cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Real-world efficacy & safety data: CAR-T in DLBCL

Matthew Frigault • 1 Sep 2020

Related Videos

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Nirav Shah • 15 Feb 2023

Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL

Nirav Shah • 15 Feb 2023

The importance of managing hematologic toxicity associated with CAR-T therapy

Marion Subklewe • 10 Feb 2023

CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL

Constantine Tam • 12 Dec 2022